Medicare Enrolled
Dr. Gustavo Fonseca, MD
Hematology · Lecanto, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Fonseca from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Fonseca? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Fonseca
Dr. Gustavo Fonseca is a hematology in Lecanto, FL, with 19 years in practice. Based on federal Medicare data, Dr. Fonseca performed 215,918 Medicare services across 4,614 unique beneficiaries.
Between the years covered by Open Payments, Dr. Fonseca received a total of $178,751 from 74 pharmaceutical and/or device companies across 750 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Fonseca is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 19% volume in FL$ $178,751 industry payments
Medicare Practice Summary
Medicare Utilization ↗215,918
Medicare services
Top 19% in FL for hematology
4,614
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~11,364 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 64,770 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 21,200 | $43 | $137 |
| Oxaliplatin chemotherapy injection | 18,400 | $0 | $12 |
| Filgrastim injection (Zarxio) for white blood cells | 16,080 | $0 | $2 |
| Nivolumab injection (Opdivo) | 15,720 | $24 | $72 |
| Anti-nausea injection (aprepitant) | 15,210 | $1 | $5 |
| Epoetin alfa injection (Procrit) for anemia | 13,360 | $6 | $23 |
| Filgrastim injection (Nivestym) for white blood cells | 12,540 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 8,460 | $18 | $51 |
| Injection, decitabine, 1 mg | 5,800 | $1 | $42 |
| Immune globulin infusion (Gammagard) | 3,616 | $36 | $108 |
| Complete blood count (CBC) with differential | 2,889 | $8 | $29 |
| Blood draw (venipuncture) | 2,785 | $8 | $9 |
| Dexamethasone injection (steroid) | 2,147 | $0 | $3 |
| Office visit, established patient (30-39 min) | 1,927 | $95 | $339 |
| Iron infusion (Monoferric) | 1,900 | $17 | $57 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,540 | $1 | $28 |
| Office visit, established patient (20-29 min) | 917 | $64 | $239 |
| Drug injection, under skin or into muscle | 909 | $10 | $69 |
| Injection, leucovorin calcium, per 50 mg | 733 | $3 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 654 | $95 | $378 |
| Anti-nausea injection (ondansetron/Zofran) | 616 | $0 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 509 | $22 | $84 |
| Injection, fluorouracil, 500 mg | 424 | $2 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 288 | $47 | $189 |
| Injection, carboplatin, 50 mg | 230 | $2 | $41 |
| Administration of chemotherapy into vein, each additional hour | 222 | $21 | $79 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 206 | $1 | $6 |
| Injection, diphenhydramine hcl, up to 50 mg | 179 | $1 | $3 |
| Injection of additional new drug or substance into vein | 166 | $11 | $61 |
| Injection, zoledronic acid, 1 mg | 151 | $6 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 109 | $16 | $56 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 108 | $24 | $89 |
| Administration of additional new drug or substance into vein, 1 hour or less | 101 | $42 | $178 |
| Infusion into a vein for hydration, each additional hour | 91 | $10 | $42 |
| Infusion, normal saline solution , 1000 cc | 91 | $2 | $7 |
| Injection, magnesium sulfate, per 500 mg | 84 | $1 | $2 |
| Office visit, established patient, complex (40-54 min) | 73 | $135 | $474 |
| Prothrombin time test (blood clotting) | 70 | $4 | $15 |
| Infusion into a vein for hydration, 31-60 minutes | 70 | $25 | $156 |
| Administration of additional new drug or substance into vein using push technique | 70 | $42 | $170 |
| Red blood count automated, with additional calculations | 60 | $5 | $20 |
| Automated urinalysis | 59 | $2 | $8 |
| New patient office visit (45-59 min) | 53 | $124 | $453 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 52 | $15 | $56 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 49 | $1 | $7 |
| New patient office visit (30-44 min) | 41 | $80 | $298 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 41 | $121 | $637 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 34 | $17 | $59 |
| Injection of drug or substance into vein | 32 | $27 | $156 |
| Initial hospital admission, high complexity | 30 | $137 | $556 |
| Drawing of blood for a medical problem | 25 | $62 | $277 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 15 | $122 | $467 |
| New patient office visit, complex (60-74 min) | 12 | $158 | $585 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
33.2% high complexity
62.6% medium
4.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$178,751
Total received (2018-2024)
Avg $25,536/year across 7 years
Top 2% in FL for hematology
74
Companies
750
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$103,456 (57.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$61,844 (34.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,451 (7.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$21,392
2023$7,336
2022$19,370
2021$9,994
2020$26,230
2019$59,682
2018$34,747
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$101,572
Celgene Corporation
$13,450
GENZYME CORPORATION
$12,866
Genmab U.S., Inc.
$7,089
Gilead Sciences, Inc.
$5,841
PFIZER INC.
$4,689
Acceleron Pharma, Inc.
$4,495
E.R. Squibb & Sons, L.L.C.
$4,153
Janssen Biotech, Inc.
$3,323
Novartis Pharmaceuticals Corporation
$1,738
Daiichi Sankyo Inc.
$1,668
Pharmacyclics LLC, An AbbVie Company
$1,592
MorphoSys, US Inc.
$1,440
AbbVie Inc.
$1,400
Janssen Scientific Affairs, LLC
$1,377
Epizyme, Inc.,
$1,272
Bayer HealthCare Pharmaceuticals Inc.
$1,057
Adaptive Biotechnologies Corporation
$1,034
AstraZeneca Pharmaceuticals LP
$955
Incyte Corporation
$713
Seagen Inc.
$518
Merck Sharp & Dohme LLC
$432
Kite Pharma, Inc.
$405
Blueprint Medicines Corporation
$395
GlaxoSmithKline, LLC.
$379
Lilly USA, LLC
$301
Genentech USA, Inc.
$287
BeiGene USA, Inc.
$287
G1 Therapeutics, Inc.
$283
Eisai Inc.
$272
EMD Serono, Inc.
$251
Merck Sharp & Dohme Corporation
$227
ADC Therapeutics America, Inc.
$227
Bayer Healthcare Pharmaceuticals Inc.
$222
EISAI INC.
$211
Regeneron Healthcare Solutions, Inc.
$181
TESARO, Inc.
$167
PUMA BIOTECHNOLOGY, INC.
$164
Takeda Pharmaceuticals U.S.A., Inc.
$142
Lexicon Pharmaceuticals, Inc.
$130
Genentech, Inc.
$101
Seattle Genetics, Inc.
$95
JAZZ PHARMACEUTICALS INC.
$89
Ethicon US, LLC
$86
AMAG Pharmaceuticals, Inc.
$85
ARRAY BIOPHARMA INC
$78
Verastem, Inc.
$77
ABBVIE INC.
$73
TerSera Therapeutics LLC
$68
Clovis Oncology, Inc.
$66
Astellas Pharma US Inc
$61
Boehringer Ingelheim Pharmaceuticals, Inc.
$55
Dendreon Pharmaceuticals LLC
$52
CTI BioPharma Corp.
$46
Heron Therapeutics, Inc.
$45
Myriad Genetic Laboratories, Inc.
$41
Mirati Therapeutics, Inc.
$38
Karyopharm Therapeutics Inc.
$37
Deciphera Pharmaceuticals Inc.
$36
Aveo Pharmaceuticals, Inc.
$35
Puma Biotechnology, Inc.
$32
Agios Pharmaceuticals, Inc.
$26
SOBI, INC
$26
Stemline Therapeutics Inc.
$25
PharmaEssentia USA Corporation
$25
TAIHO ONCOLOGY, INC.
$21
Rigel Pharmaceuticals, Inc.
$20
Pharmacosmos Therapeutics Inc.
$19
AVEO Pharmaceuticals, Inc.
$18
Alexion Pharmaceuticals, Inc.
$17
F. Hoffmann-La Roche AG
$15
CSL Behring
$13
Aurobindo Pharma USA, Inc.
$13
Ipsen Biopharmaceuticals, Inc
$12
Top 3 companies account for 71.5% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · ALUNBRIG · AUGTYRO · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRACANALYSIS CDX · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CALQUENCE · CARVYKTI · CEREZYME · COSELA · CYRAMZA · Cinvanti · Columvi · Copiktra · DARZALEX · DOPTELET · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · EVENITY · EXKIVITY · Enhertu · Epkinly · Erleada · FERAHEME · FOTIVDA · Fedratinib · Folotyn · GAZYVA · GILOTRIF · Halaven · Hizentra · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Idhifa · Imbruvica · Inrebic · Istodax · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MYRISK · NERLYNX · Nerlynx · Nexavar · Non-Covered Product · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Perjeta · Phesgo · Pomalyst · Prolia · QINLOCK · REBLOZYL · RYBREVANT · Reblozyl · Revlimid · Rezlidhia · Rubraca · SARCLISA · SOLIRIS · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Trodelvy · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Vitrakvi · Vonjo · XALKORI · XGEVA · XPOVIO · XTANDI · Xermelo · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (58%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for hematology in FL.
Equivalent to $83 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
9
Per 100K population
5.7
County median income
$55,355
Nearest hospital
HCA FLORIDA CITRUS HOSPITAL
7.4 mi
7.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Fonseca is a mixed practice specialist, with above-average Medicare volume (top 19% in FL), and high industry engagement (speaking/promotional, top 2%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Fonseca experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Fonseca performed 64,770 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Fonseca receive payments from pharmaceutical companies?
Yes. Dr. Fonseca received a total of $178,751 from 74 companies across 750 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Fonseca's costs compare to other hematologys in Lecanto?
Dr. Fonseca's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Fonseca) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Lecanto
Browse hematologys in Lecanto ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology